Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey

BİLEN, Yusuf; Erdem, Fuat

doi:10.3906/sag-1004-783

Makale Tam Makale Uluslararası 2012

Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey

Yusuf BİLEN, Fuat Erdem

TURKISH JOURNAL OF MEDICAL SCIENCES Cilt 42 · Sayı 1 · ss. 31–38 · 01.02.2012

DOI ile aç

Özet

Aim: To validate patient responses to imatinib mesylate, which induces hematologic and cytogenetic remission and, consequently, modifies the progression of chronic myeloid leukemia (CML).

Atıf için künye

BİLEN, Y., & Erdem, F. (2012). Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey. TURKISH JOURNAL OF MEDICAL SCIENCES, 42(1), 31–38. https://doi.org/10.3906/sag-1004-783

BibTeX

@article{bilen2012-228527,
  author = {BİLEN, Yusuf and Erdem, Fuat},
  title = {Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey},
  journal = {TURKISH JOURNAL OF MEDICAL SCIENCES},
  year = {2012},
  volume = {42},
  number = {1},
  pages = {31--38},
  issn = {1300-0144},
  doi = {10.3906/sag-1004-783},
  url = {https://akademik.atauni.edu.tr/yayinlar/228527-hematologic-cytogenetic-and-molecular-responses-to-imatinib-therapy-for-chronic}
}